ZTS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

ZT

Mkt Cap

$29.50B

Volume

1.73K

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to NoteZoetis stock declined 2.22% to $71.40, underperforming the broader market gains. The animal health company faces headwinds with projected EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The company holds a Zacks Rank of #5 (Strong Sell) despite trading at a Forward P/E discount to its industry average.Zacks Investment Research · Sep 18, 2026

Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030A comprehensive 249-page veterinary diagnostics market report covering 15 countries and 32 companies has been released, forecasting market trends through 2030. The report analyzes growth drivers including pet ownership patterns, agricultural modernization, and the One Health movement, while examining competitive positioning of major players like IDEXX, Zoetis, Antech, Roche, and Thermo Fisher across various diagnostic assay types, animal categories, and applications.GlobeNewswire Inc. · Sep 7, 2026

Global Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal HealthcareThe global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.GlobeNewswire Inc. · Aug 25, 2026

DEADLINE ALERT for AVAV, CALX, ZTS, and LCID: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersClass action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.GlobeNewswire Inc. · Jul 27, 2026

ZOETIS DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important July 27 Deadline in Securities Class Action – ZTSA securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales in dermatology products Apoquel and Cytopoint. Investors who purchased securities during this period may be eligible for compensation.GlobeNewswire Inc. · Jul 23, 2026

ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th: Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff DeadlineA class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts during the period from January 14, 2025 to May 6, 2026. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply to be appointed as lead plaintiff.GlobeNewswire Inc. · Jul 20, 2026

Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitA securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and declining sales of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. The deadline to file a lead plaintiff motion is July 27, 2026.GlobeNewswire Inc. · Jul 20, 2026

ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTSA securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities during this period may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.GlobeNewswire Inc. · Jul 19, 2026

Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLPA securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to file for lead plaintiff status.GlobeNewswire Inc. · Jul 18, 2026

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTSA securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period of January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its flagship products Librela, Simparica Trio, and dermatology treatments Apoquel and Cytopoint due to safety concerns, competition, and market share losses. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.GlobeNewswire Inc. · Jul 16, 2026

ZT

ZTSZOETIS INC.

ZTS

Pay with—

Available Balance0.00

Your PositionYou don't own any ZTS yet.

Related Tickers

Earnings

Dividends

Last · Jul 20Quarterly

Amount$0.53

Yield2.93%

Annual$2.09